Novo Nordisk A/S (NONOF)
USD 69.9
(6.72%)
USD 69.9
(6.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 102.57 Billion DKK | 37.11% |
| 2022 | 74.8 Billion DKK | 27.56% |
| 2021 | 58.64 Billion DKK | 8.35% |
| 2020 | 54.12 Billion DKK | 3.13% |
| 2019 | 52.48 Billion DKK | 11.08% |
| 2018 | 47.24 Billion DKK | -3.51% |
| 2017 | 48.96 Billion DKK | 1.1% |
| 2016 | 48.43 Billion DKK | -2.05% |
| 2015 | 49.44 Billion DKK | 43.35% |
| 2014 | 34.49 Billion DKK | 9.52% |
| 2013 | 31.49 Billion DKK | 6.85% |
| 2012 | 29.47 Billion DKK | 31.73% |
| 2011 | 22.37 Billion DKK | 18.44% |
| 2010 | 18.89 Billion DKK | 26.51% |
| 2009 | 14.93 Billion DKK | 20.38% |
| 2008 | 12.4 Billion DKK | 38.53% |
| 2007 | 8.95 Billion DKK | -1.81% |
| 2006 | 9.12 Billion DKK | 12.94% |
| 2005 | 8.07 Billion DKK | 14.87% |
| 2004 | 7.02 Billion DKK | 9.78% |
| 2003 | 6.4 Billion DKK | 7.2% |
| 2002 | 5.97 Billion DKK | 6.72% |
| 2001 | 5.59 Billion DKK | 31.91% |
| 2000 | 4.24 Billion DKK | 17.37% |
| 1999 | 3.61 Billion DKK | 74.92% |
| 1998 | 2.06 Billion DKK | -11.46% |
| 1997 | 2.33 Billion DKK | 17.88% |
| 1996 | 1.98 Billion DKK | 5.74% |
| 1995 | 1.87 Billion DKK | 1.77% |
| 1994 | 1.84 Billion DKK | -5.35% |
| 1993 | 1.94 Billion DKK | 67.8% |
| 1992 | 1.15 Billion DKK | -17.48% |
| 1991 | 1.4 Billion DKK | 33.4% |
| 1990 | 1.05 Billion DKK | 0.23% |
| 1989 | 1.04 Billion DKK | 12.14% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 32.41 Billion DKK | 21.1% |
| 2024 Q2 | 25.52 Billion DKK | -19.99% |
| 2023 FY | 102.57 Billion DKK | 37.11% |
| 2023 Q3 | 26.91 Billion DKK | 12.66% |
| 2023 Q4 | 26.76 Billion DKK | -0.55% |
| 2023 Q1 | 25 Billion DKK | 46.35% |
| 2023 Q2 | 23.88 Billion DKK | -4.47% |
| 2022 Q1 | 19.14 Billion DKK | 40.44% |
| 2022 Q3 | 20.18 Billion DKK | 9.75% |
| 2022 FY | 74.8 Billion DKK | 27.56% |
| 2022 Q2 | 18.39 Billion DKK | -3.95% |
| 2022 Q4 | 17.08 Billion DKK | -15.34% |
| 2021 Q3 | 15.24 Billion DKK | 3.18% |
| 2021 Q4 | 13.63 Billion DKK | -10.59% |
| 2021 Q1 | 14.98 Billion DKK | 34.03% |
| 2021 Q2 | 14.77 Billion DKK | -1.35% |
| 2021 FY | 58.64 Billion DKK | 8.35% |
| 2020 Q4 | 11.17 Billion DKK | -12.73% |
| 2020 Q2 | 13.83 Billion DKK | -15.11% |
| 2020 Q1 | 16.3 Billion DKK | 37.3% |
| 2020 Q3 | 12.8 Billion DKK | -7.44% |
| 2020 FY | 54.12 Billion DKK | 3.13% |
| 2019 Q4 | 11.87 Billion DKK | -8.1% |
| 2019 Q1 | 14.23 Billion DKK | 32.05% |
| 2019 Q2 | 13.45 Billion DKK | -5.53% |
| 2019 Q3 | 12.91 Billion DKK | -3.96% |
| 2019 FY | 52.48 Billion DKK | 11.08% |
| 2018 Q2 | 12.2 Billion DKK | -1.96% |
| 2018 Q4 | 10.78 Billion DKK | -8.72% |
| 2018 Q1 | 12.44 Billion DKK | 23.9% |
| 2018 FY | 47.24 Billion DKK | -3.51% |
| 2018 Q3 | 11.81 Billion DKK | -3.2% |
| 2017 Q3 | 12.04 Billion DKK | -10.03% |
| 2017 FY | 48.96 Billion DKK | 1.1% |
| 2017 Q2 | 13.38 Billion DKK | -0.77% |
| 2017 Q4 | 10.04 Billion DKK | -16.58% |
| 2017 Q1 | 13.49 Billion DKK | 20.38% |
| 2016 Q3 | 12.42 Billion DKK | -0.62% |
| 2016 Q4 | 11.2 Billion DKK | -9.77% |
| 2016 Q1 | 12.3 Billion DKK | 10.64% |
| 2016 Q2 | 12.49 Billion DKK | 1.53% |
| 2016 FY | 48.43 Billion DKK | -2.05% |
| 2015 Q4 | 11.12 Billion DKK | -7.14% |
| 2015 Q3 | 11.98 Billion DKK | -4.02% |
| 2015 Q1 | 13.85 Billion DKK | 51.33% |
| 2015 Q2 | 12.48 Billion DKK | -9.92% |
| 2015 FY | 49.44 Billion DKK | 43.35% |
| 2014 Q3 | 8.56 Billion DKK | -1.88% |
| 2014 FY | 34.49 Billion DKK | 9.52% |
| 2014 Q1 | 8.03 Billion DKK | 9.23% |
| 2014 Q2 | 8.73 Billion DKK | 8.71% |
| 2014 Q4 | 9.15 Billion DKK | 6.86% |
| 2013 Q4 | 7.35 Billion DKK | -7.98% |
| 2013 FY | 31.49 Billion DKK | 6.85% |
| 2013 Q1 | 7.56 Billion DKK | -0.13% |
| 2013 Q2 | 8.58 Billion DKK | 13.53% |
| 2013 Q3 | 7.99 Billion DKK | -6.91% |
| 2012 Q1 | 6.38 Billion DKK | 5.0% |
| 2012 Q4 | 7.57 Billion DKK | -3.71% |
| 2012 FY | 29.47 Billion DKK | 31.73% |
| 2012 Q3 | 7.86 Billion DKK | 2.76% |
| 2012 Q2 | 7.65 Billion DKK | 19.86% |
| 2011 FY | 22.37 Billion DKK | 18.44% |
| 2011 Q2 | 5.26 Billion DKK | -2.82% |
| 2011 Q3 | 5.61 Billion DKK | 6.55% |
| 2011 Q4 | 6.08 Billion DKK | 8.4% |
| 2011 Q1 | 5.41 Billion DKK | 24.72% |
| 2010 Q1 | 4.38 Billion DKK | 36.13% |
| 2010 Q2 | 5.04 Billion DKK | 15.04% |
| 2010 Q3 | 5.12 Billion DKK | 1.65% |
| 2010 Q4 | 4.34 Billion DKK | -15.22% |
| 2010 FY | 18.89 Billion DKK | 26.51% |
| 2009 FY | 14.93 Billion DKK | 20.38% |
| 2009 Q3 | 3.81 Billion DKK | -6.75% |
| 2009 Q2 | 4.09 Billion DKK | 7.35% |
| 2009 Q1 | 3.81 Billion DKK | 11.62% |
| 2009 Q4 | 3.21 Billion DKK | -15.6% |
| 2008 Q4 | 3.41 Billion DKK | 2.8% |
| 2008 FY | 12.4 Billion DKK | 38.53% |
| 2008 Q2 | 2.84 Billion DKK | 0.71% |
| 2008 Q1 | 2.82 Billion DKK | 147.9% |
| 2008 Q3 | 3.32 Billion DKK | 16.57% |
| 2007 Q2 | 2.81 Billion DKK | 20.78% |
| 2007 Q4 | 1.14 Billion DKK | -57.42% |
| 2007 FY | 8.95 Billion DKK | -1.81% |
| 2007 Q1 | 2.32 Billion DKK | 10.67% |
| 2007 Q3 | 2.67 Billion DKK | -4.68% |
| 2006 Q1 | 1.88 Billion DKK | -1.67% |
| 2006 FY | 9.12 Billion DKK | 12.94% |
| 2006 Q4 | 2.1 Billion DKK | -16.08% |
| 2006 Q2 | 2.63 Billion DKK | 39.76% |
| 2006 Q3 | 2.5 Billion DKK | -4.82% |
| 2005 Q4 | 1.91 Billion DKK | -16.98% |
| 2005 FY | 8.07 Billion DKK | 14.87% |
| 2005 Q3 | 2.3 Billion DKK | -1.33% |
| 2005 Q2 | 2.33 Billion DKK | 54.72% |
| 2005 Q1 | 1.51 Billion DKK | -17.65% |
| 2004 Q4 | 1.83 Billion DKK | 3.62% |
| 2004 FY | 7.02 Billion DKK | 9.78% |
| 2004 Q3 | 1.77 Billion DKK | 3.45% |
| 2004 Q1 | 1.5 Billion DKK | -17.5% |
| 2004 Q2 | 1.71 Billion DKK | 13.81% |
| 2003 Q1 | 1.31 Billion DKK | 110.55% |
| 2003 Q4 | 1.82 Billion DKK | 11.4% |
| 2003 Q3 | 1.63 Billion DKK | 1.81% |
| 2003 FY | 6.4 Billion DKK | 7.2% |
| 2003 Q2 | 1.6 Billion DKK | 21.93% |
| 2002 Q1 | 6.02 Billion DKK | 151.82% |
| 2002 Q2 | 5.27 Billion DKK | -12.32% |
| 2002 Q3 | 6.44 Billion DKK | 22.11% |
| 2002 Q4 | -12.49 Billion DKK | -293.91% |
| 2002 FY | 5.97 Billion DKK | 6.72% |
| 2001 Q1 | 5.34 Billion DKK | 137.11% |
| 2001 FY | 5.59 Billion DKK | 31.91% |
| 2001 Q4 | -11.61 Billion DKK | -274.63% |
| 2001 Q3 | 6.65 Billion DKK | 15.78% |
| 2001 Q2 | 5.74 Billion DKK | 7.47% |
| 2000 Q2 | 6.48 Billion DKK | 16.57% |
| 2000 Q3 | 15.34 Billion DKK | 136.62% |
| 2000 FY | 4.24 Billion DKK | 17.37% |
| 2000 Q4 | -14.4 Billion DKK | -193.88% |
| 2000 Q1 | 5.56 Billion DKK | 147.28% |
| 1999 Q2 | 5.02 Billion DKK | 8.45% |
| 1999 Q4 | -11.76 Billion DKK | -302.07% |
| 1999 FY | 3.61 Billion DKK | 74.92% |
| 1999 Q1 | 4.63 Billion DKK | 142.23% |
| 1999 Q3 | 5.82 Billion DKK | 15.94% |
| 1998 Q2 | 4.56 Billion DKK | 8.95% |
| 1998 Q1 | 4.19 Billion DKK | 142.09% |
| 1998 Q4 | -10.96 Billion DKK | -317.84% |
| 1998 FY | 2.06 Billion DKK | -11.46% |
| 1998 Q3 | 5.03 Billion DKK | 10.22% |
| 1997 Q4 | -9.96 Billion DKK | -330.83% |
| 1997 Q2 | 4.12 Billion DKK | 13.72% |
| 1997 Q1 | 3.62 Billion DKK | 141.58% |
| 1997 FY | 2.33 Billion DKK | 17.88% |
| 1997 Q3 | 4.31 Billion DKK | 4.63% |
| 1996 FY | 1.98 Billion DKK | 5.74% |
| 1996 Q4 | -8.72 Billion DKK | -337.73% |
| 1996 Q3 | 3.66 Billion DKK | 4.6% |
| 1996 Q2 | 3.5 Billion DKK | 2.12% |
| 1996 Q1 | 3.43 Billion DKK | 140.75% |
| 1995 FY | 1.87 Billion DKK | 1.77% |
| 1995 Q4 | -8.42 Billion DKK | -361.95% |
| 1995 Q3 | 3.21 Billion DKK | -9.94% |
| 1995 Q2 | 3.57 Billion DKK | 6.01% |
| 1995 Q1 | 3.37 Billion DKK | 141.51% |
| 1994 Q1 | 3.11 Billion DKK | 144.7% |
| 1994 FY | 1.84 Billion DKK | -5.35% |
| 1994 Q4 | -8.12 Billion DKK | -340.61% |
| 1994 Q3 | 3.37 Billion DKK | -1.4% |
| 1994 Q2 | 3.42 Billion DKK | 10.02% |
| 1993 Q4 | -6.96 Billion DKK | -322.29% |
| 1993 Q2 | 3 Billion DKK | 14.37% |
| 1993 Q3 | 3.13 Billion DKK | 4.25% |
| 1993 Q1 | 2.62 Billion DKK | 138.63% |
| 1993 FY | 1.94 Billion DKK | 67.8% |
| 1992 Q2 | 2.8 Billion DKK | 5.54% |
| 1992 Q1 | 2.66 Billion DKK | 148.56% |
| 1992 Q4 | -6.79 Billion DKK | -364.96% |
| 1992 FY | 1.15 Billion DKK | -17.48% |
| 1992 Q3 | 2.56 Billion DKK | -8.67% |
| 1991 Q4 | -5.48 Billion DKK | -329.06% |
| 1991 Q1 | 2.27 Billion DKK | 145.95% |
| 1991 Q2 | 2.24 Billion DKK | -1.2% |
| 1991 Q3 | 2.39 Billion DKK | 6.4% |
| 1991 FY | 1.4 Billion DKK | 33.4% |
| 1990 Q3 | 2.02 Billion DKK | -0.11% |
| 1990 Q4 | -4.95 Billion DKK | -344.08% |
| 1990 Q2 | 2.03 Billion DKK | 4.7% |
| 1990 FY | 1.05 Billion DKK | 0.23% |
| 1990 Q1 | 1.94 Billion DKK | 143.86% |
| 1989 Q3 | 1.74 Billion DKK | -0.53% |
| 1989 Q1 | 1.97 Billion DKK | 164.62% |
| 1989 Q2 | 1.75 Billion DKK | -11.07% |
| 1989 Q4 | -4.42 Billion DKK | -353.14% |
| 1989 FY | 1.04 Billion DKK | 12.14% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 2685179.92% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 142988.586% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 39191468.072% |
| SQZ Biotechnologies Company | -75.82 Million USD | 135377.283% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 3598547.574% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 574840.853% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -125216.572% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 6677881.763% |
| Marizyme, Inc. | -34.08 Million USD | 301022.511% |
| Genus plc | 6.4 Million USD | -1602618.75% |
| Pharming Group N.V. | -4.87 Million USD | 2102222.657% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 5163708.576% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 11013220.316% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 1228531.138% |
| ContraFect Corporation | -56.88 Million USD | 180405.507% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 7316409.448% |
| IMV Inc. | -38.67 Million USD | 265344.341% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 3728926.005% |
| ONE Bio Corp. | 13.68 Million USD | -749625.049% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 173983.709% |
| Mesoblast Limited | -84.14 Million USD | 121998.582% |
| MultiCell Technologies, Inc. | -722.81 USD | 14191004651.68% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -2897470.621% |
| Genscript Biotech Corporation | -415.79 Million USD | 24769.606% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 26330156.216% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 3903930.301% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2086938.545% |
| Biomind Labs Inc. | -1 Million USD | 10159935.104% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 3535610.556% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 1543026.723% |
| Skye Bioscience, Inc. | -13.67 Million USD | 750359.659% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 5501904.899% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -1052755.342% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 342461371.368% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 2252134.48% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 2033489.745% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 646449.716% |
| Accustem Sciences Inc. | -3.74 Million USD | 2738021.199% |
| EV Biologics, Inc. | -483.06 Thousand USD | 21234227.296% |
| Q BioMed Inc. | -3.44 Million USD | 2977042.294% |
| GB Sciences, Inc. | -1.42 Million USD | 7221032.778% |
| Alpha Cognition Inc. | -9.7 Million USD | 1056953.666% |
| CSL Limited | 3.7 Billion USD | -2670.773% |
| Agentix Corp. | -1.37 Million USD | 7477668.897% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 186691.963% |
| Enzolytics Inc. | -2.14 Million USD | 4773648.027% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 804665.064% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 3237635.642% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 5307637.475% |
| argenx SE | -425.04 Million USD | 24232.277% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 184891.381% |
| HST Global, Inc. | -140.9 Thousand USD | 72795631.805% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 9825195.785% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 9118550.786% |
| Halberd Corporation | -75.05 Thousand USD | 136674317.189% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 3513577.224% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 3012570.855% |
| Zenith Capital Corp. | -8.94 Million USD | 1147075.288% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 6494776.624% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 4177727.573% |
| AVAX Technologies, Inc. | 6.69 Million USD | -1532483.88% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 59806685.686% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 5116630.333% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 588795232.312% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | 4158348.066% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 10423725.557% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 8166819.745% |
| Kadimastem Ltd | -3.04 Million USD | 3373967.281% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 1318706.617% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 56519371.565% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 7681065.92% |
| LadRx Corporation | -3.82 Million USD | 2682736.848% |
| Cell Source, Inc. | -4.32 Million USD | 2371563.462% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 24688231.049% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 14931899.985% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 14931899.985% |
| Affymax, Inc. | -15.04 Million USD | 681836.01% |
| Mobile Lads Corp. | -554.55 Thousand USD | 18496899.207% |
| Itoco Inc. | -919.14 Thousand USD | 11159879.794% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 2420203.369% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 9166677.301% |
| International Stem Cell Corporation | -663 Thousand USD | 15471291.554% |
| CytoDyn Inc. | -18.05 Million USD | 568125.252% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 407524931.148% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 46608120.793% |
| Qrons Inc. | -643.67 Thousand USD | 15935732.312% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 18163695.249% |
| SYBLEU INC | -149.18 Thousand USD | 68758646.722% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 4600080.537% |
| Rebus Holdings, Inc. | -664 Thousand USD | 15447991.566% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 5647452.889% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 194859522.492% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 504297051.819% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 282937.92% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 6339655.006% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 13939909.876% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 3297239.184% |
| Neutra Corp. | -229.48 Thousand USD | 44697380.008% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 584933.799% |
| PureTech Health plc | -146.19 Million USD | 70260.535% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 477385.502% |
| IXICO plc | -1.43 Million USD | 7138165.414% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 1080850.184% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 84310.958% |
| CSL Limited | 3.81 Billion USD | -2590.818% |
| Cellectis S.A. | -108.85 Million USD | 94327.905% |